Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Total Current Liabilities data on file, last reported at $1.5 billion in Q2 2026.

• Quarterly Total Current Liabilities rose 16.27% year-over-year to $1.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 16.27% YoY) and the FY2025 annual result came in at $1.5 billion, up 23.61% from the prior year.
• Total Current Liabilities rose to $1.5 billion in Q2 2026, from $1.3 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.6 billion in Q3 2025 to a low of $606.0 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities climbed 10.38% — and 2024, when it surged 39.85%.
• Tracing ALNY's Total Current Liabilities over 5 years: stood at $767.9 million in 2022, then increased by 26.03% to $967.8 million in 2023, then rose by 22.58% to $1.2 billion in 2024, then increased by 23.61% to $1.5 billion in 2025, then increased by 3.15% to $1.5 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.5 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.